C2 PHARMA, a manufacturer and supplier of ophthalmic and niche active pharmaceutical ingredients (APIs), announced the approval of a C-DMF for Digoxin, an API manufactured by their Polish manufacturing partner Nobilus Ent. This milestone comes after a challenging three-year journey, due to global disruptions caused by the COVID pandemic.
The approval covers both Digoxin and Digoxin micronized. It supports different dosage forms i.e., oral and injectable drug product formulations. Digoxin is derived from the leaves of the Digitalis lanata plant and as a cardiac glycoside, it is commonly used in clinical practice for the treatment of mild to moderate heart failure.
“As a result of this approval, we can now commercialize Digoxin in China. The Chinese customers that have received samples or quantities for exhibit batches of Digoxin can now apply using the API for their finished dosage form,” said Katrien Oosterom, Vice President of Regulatory Affairs. “For China, this implies that another international source of Digoxin will now enter the market and C2 PHARMA now holds the registration of the only European manufactured Digoxin, an achievement that not only expands our global reach, but also marks a stride towards providing access to high-quality medication for local patients.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!